Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02980874




Registration number
NCT02980874
Ethics application status
Date submitted
30/11/2016
Date registered
2/12/2016
Date last updated
14/04/2021

Titles & IDs
Public title
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Scientific title
SAPPHIRE: A Randomized, Masked, Controlled Trial To Study The Safety And Efficacy Of Suprachoroidal CLS-TA In Conjunction With Intravitreal Aflibercept In Subjects With Retinal Vein Occlusion
Secondary ID [1] 0 0
CLS1003-301
Universal Trial Number (UTN)
Trial acronym
SAPPHIRE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Macular Edema 0 0
Retinal Vein Occlusion 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - suprachoroidal CLS-TA
Treatment: Drugs - suprachoroidal sham
Treatment: Drugs - IVT aflibercept

Experimental: Active - IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections

Active Comparator: Control - IVT aflibercept (2 mg/0.05 mL) + sham SC procedure


Treatment: Drugs: suprachoroidal CLS-TA
suprachoroidal injection of CLS-TA

Treatment: Drugs: suprachoroidal sham
suprachoroidal sham procedure

Treatment: Drugs: IVT aflibercept
2 mg intravitreal injection of aflibercept
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of Subjects Demonstrating = 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)
Timepoint [1] 0 0
2 months
Secondary outcome [1] 0 0
Mean Change From Baseline in Best Corrected Visual Acuity
Timepoint [1] 0 0
6 months
Secondary outcome [2] 0 0
Mean Change From Baseline in Central Subfield Thickness
Timepoint [2] 0 0
6 months

Eligibility
Key inclusion criteria
- Has a clinical diagnosis of RVO in the study eye

- Has a CST of = 300 µm in the study eye

- Has an ETDRS BCVA score of = 20 letters read and = 70 letters read in the study eye;

- Is naïve to local pharmacologic treatment for RVO in the study eye;
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any active ocular disease or infection in the study eye other than RVO

- History of glaucoma, intraocular pressure > 21 mmHg or ocular hypertension requiring
more than one medication

- Any uncontrolled systemic disease that, in the opinion of the Investigator, would
preclude participation in the study

- Any evidence of neovascularization in the study eye

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
31/01/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/12/2018
Sample size
Target
Accrual to date
Final
460
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Strathfield Retina Clinic - Strathfield
Recruitment hospital [2] 0 0
Save Site Institute, University of Sydney, Sydney Eye Hospital - Sydney
Recruitment hospital [3] 0 0
Sydney Retina Clinic and Day Surgery - Sydney
Recruitment hospital [4] 0 0
Marsden Eye Specialists - Sydney
Recruitment hospital [5] 0 0
The Royal Victorian Eye and Ear Hospital - East Melbourne
Recruitment hospital [6] 0 0
Specialist Eye Group - Melbourne
Recruitment postcode(s) [1] 0 0
2135 - Strathfield
Recruitment postcode(s) [2] 0 0
2000 - Sydney
Recruitment postcode(s) [3] 0 0
2150 - Sydney
Recruitment postcode(s) [4] 0 0
3002 - East Melbourne
Recruitment postcode(s) [5] 0 0
3150 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Hawaii
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Dakota
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Austria
State/province [24] 0 0
Graz
Country [25] 0 0
Austria
State/province [25] 0 0
Linz
Country [26] 0 0
Canada
State/province [26] 0 0
British Columbia
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
Denmark
State/province [29] 0 0
Glostrup
Country [30] 0 0
Denmark
State/province [30] 0 0
Roskilde
Country [31] 0 0
Hungary
State/province [31] 0 0
Budapest
Country [32] 0 0
Hungary
State/province [32] 0 0
Debrecen
Country [33] 0 0
Hungary
State/province [33] 0 0
Pecs
Country [34] 0 0
India
State/province [34] 0 0
Gujarat
Country [35] 0 0
India
State/province [35] 0 0
Maharashtra
Country [36] 0 0
India
State/province [36] 0 0
New Delhi
Country [37] 0 0
India
State/province [37] 0 0
Tamil Nadu
Country [38] 0 0
India
State/province [38] 0 0
Telangana
Country [39] 0 0
India
State/province [39] 0 0
West Bengal
Country [40] 0 0
Israel
State/province [40] 0 0
Haifa
Country [41] 0 0
Italy
State/province [41] 0 0
Milan
Country [42] 0 0
Philippines
State/province [42] 0 0
Cebu City
Country [43] 0 0
Philippines
State/province [43] 0 0
Makati City
Country [44] 0 0
Philippines
State/province [44] 0 0
Pasig City
Country [45] 0 0
Poland
State/province [45] 0 0
Bydgoszcz
Country [46] 0 0
Poland
State/province [46] 0 0
Gdansk
Country [47] 0 0
Poland
State/province [47] 0 0
Lublin
Country [48] 0 0
Poland
State/province [48] 0 0
Olsztyn
Country [49] 0 0
Portugal
State/province [49] 0 0
Braga
Country [50] 0 0
Portugal
State/province [50] 0 0
Coimbra
Country [51] 0 0
Portugal
State/province [51] 0 0
Porto
Country [52] 0 0
Slovakia
State/province [52] 0 0
Žilina
Country [53] 0 0
Spain
State/province [53] 0 0
Vizcaya
Country [54] 0 0
Spain
State/province [54] 0 0
Barcelona
Country [55] 0 0
Spain
State/province [55] 0 0
Madrid
Country [56] 0 0
Spain
State/province [56] 0 0
Oviedo
Country [57] 0 0
Spain
State/province [57] 0 0
Pamplona
Country [58] 0 0
Spain
State/province [58] 0 0
Zaragoza
Country [59] 0 0
Taiwan
State/province [59] 0 0
Kaohsiung
Country [60] 0 0
Taiwan
State/province [60] 0 0
Taipei
Country [61] 0 0
United Kingdom
State/province [61] 0 0
Belfast
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Sunderland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Clearside Biomedical, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12
months duration in treatment naïve subjects with RVO.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02980874
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Thomas Ciulla, MD MBA
Address 0 0
Clearside Biomedical, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02980874